Wall Street Journal  Feb 27  Comment 
Akorn's checkered history should have given Fresenius pause before it agreed to buy the generic-drug company.
Motley Fool  Feb 27  Comment 
An issue with "data integrity" could derail a planned acquisition of the generic drugmaker.
FiercePharma  Feb 27  Comment 
Fresenius’ $4.3 billion deal to buy out U.S. generics maker Akorn is in jeopardy as the two companies investigate allegations that Akorn violated FDA data standards during drug development.
Benzinga  Feb 27  Comment 
What Happened Akorn, Inc. (NASDAQ: AKRX) shares fell more than 30 percent Monday evening after Fresenius Kabi AG announced an independent investigation into alleged breaches of FDA data integrity requirements related to product...
MarketWatch  Feb 27  Comment 
Shares of Akorn Inc. sank 34% in premarket trading on Tuesday, after German-based Fresenius SE said it was conducting a probe into possible data breaches at the U.S. generic-drugs manufacturer. The probe could hamper a deal -- valued at more...
Benzinga  Oct 26  Comment 
On the same day President Donald Trump was expected to declare the national opioid epidemic a public health emergency, a Boston Federal Court charged John Kapoor, former CEO and chairman of the opioid producing Insys Therapeutics Inc (NASDAQ:...
FiercePharma  Oct 24  Comment 
An Akorn sterile injectables plant in Illinois is in hot water with the FDA again, but this time it may be a problem for Fresenius Kabi, which is buying the generics manufacturer in a $4.3 billion deal.

You may also be interested in articles related to Akorn (AKRX):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki